Jiangsu Recbio Technology (2179) Stock Overview
A vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
2179 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Jiangsu Recbio Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.90 |
| 52 Week High | HK$9.80 |
| 52 Week Low | HK$5.75 |
| Beta | -0.24 |
| 1 Month Change | -16.90% |
| 3 Month Change | -24.94% |
| 1 Year Change | -28.83% |
| 3 Year Change | -71.43% |
| 5 Year Change | n/a |
| Change since IPO | -76.63% |
Recent News & Updates
Shareholder Returns
| 2179 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -2.6% | -7.3% | -4.6% |
| 1Y | -28.8% | 106.3% | 34.0% |
Return vs Industry: 2179 underperformed the Hong Kong Biotechs industry which returned 106.3% over the past year.
Return vs Market: 2179 underperformed the Hong Kong Market which returned 34% over the past year.
Price Volatility
| 2179 volatility | |
|---|---|
| 2179 Average Weekly Movement | 3.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.2% |
Stable Share Price: 2179 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2179's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 507 | Yong Liu | www.recbio.cn |
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; REC604c, a recombinant HPV 9-valent vaccine; and REC604a, a novel adjuvanted recombinant HPV quadrivalent vaccine. It also develops ReCOV, a recombinant bicomponent COVID-19 vaccine candidate that is in Phase II/III trial; REC610, a recombinant shingles vaccine that is in Phase l clinical trial; and REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage.
Jiangsu Recbio Technology Co., Ltd. Fundamentals Summary
| 2179 fundamental statistics | |
|---|---|
| Market cap | HK$2.79b |
| Earnings (TTM) | -HK$710.95m |
| Revenue (TTM) | HK$31.89m |
Is 2179 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2179 income statement (TTM) | |
|---|---|
| Revenue | CN¥29.11m |
| Cost of Revenue | CN¥2.91m |
| Gross Profit | CN¥26.20m |
| Other Expenses | CN¥675.19m |
| Earnings | -CN¥648.98m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 90.00% |
| Net Profit Margin | -2,229.10% |
| Debt/Equity Ratio | 466.9% |
How did 2179 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 23:16 |
| End of Day Share Price | 2025/11/24 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jiangsu Recbio Technology Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CMB International Securities Limited |
| Sean Wu | Morgan Stanley |
| Youjue Hu | Morgan Stanley |